产品简要
公司名称 :
ACROBiosystems
产品类型 :
蛋白
产品名称 :
人类EMMPRIN/CD147蛋白, Fc标签
目录 :
CD7-H5259
规格 :
100微克, 1毫克
价格 :
260美元, 1600美元
更多信息或购买 :
产品信息
公司名称 :
ACROBiosystems
产品类型 :
蛋白
目录 :
CD7-H5259
产品名称 :
人类EMMPRIN/CD147蛋白, Fc标签
规格 :
100微克, 1毫克
价格 :
260美元, 1600美元
规格&价格 :
$260/100微克, $1600/1毫克
靶标 :
EMMPRIN
宿主物种 :
人类
By Tag :
Fc标签
研究 :
For Research Use Only
来源 :
Human EMMPRIN, Fc Tag (CD7-H5259) is expressed from human 293 cells (HEK293). It contains AA Ala 22 - His 205 (Accession # NP_940991.1).
内毒素 :
Less than 1.0 EU per μg by the LAL method.
纯度 :
>95% as determined by SDS-PAGE.
SDS-PAGE Remark(R&NR) :
Human EMMPRIN, Fc Tag on SDS-PAGE under reducing (R) condition. The gel was stained overnight with Coomassie Blue. The purity of the protein is greater than 95%.
配方 :
Lyophilized from 0.22 μm filtered solution in 50 mM Tris, 100 mM Glycine, pH7.5. Normally trehalose is added as protectant before lyophilization. Contact us for customized product form or formulation.
重组 :
Please see Certificate of Analysis for specific instructions. For best performance, we strongly recommend you to follow the reconstitution protocol provided in the CoA.
储存 :
For long term storage, the product should be stored at lyophilized state at -20°C or lower. Please avoid repeated freeze-thaw cycles. This product is stable after storage at:
● -20°C to -70°C for 12 months in lyophilized state;
● -70℃ for 3 months under sterile conditions after reconstitution.
背景 :
CD147, also known as Basigin (BSG), or extracellular matrix metalloproteinase inducer (EMMPRIN). The human basigin protein contains 269 amino acids that form two heavily glycosylated C2 type immunoglobulin-like domains at the N-terminal extracellular portion. A second form of basigin has also been characterized that contains one additional immunoglobulin-like domain in its extracellular portion. As members of the immunoglobulin superfamily play fundamental roles in intercellular recognition involved in various immunologic phenomena, differentiation, and development, basigin is thought also to play a role in intercellular recognition and regulate several distinct functions, such as spermatogenesis, expression of the monocarboxylate transporter and the responsiveness of lymphocytes. Basigin is a type I integral membrane receptor that has many ligands, including the cyclophilin (CyP) proteins Cyp-A and CyP-B and certain integrins.
参考文献 :
(1) Kasinrerk W, , et al.,1992, J Immunol 149 (3): 847–54.
(2) Yurchenko V, et al., 2006, Immunology 117 (3): 301–9.
(3) Kanekura T, et al., 2002, Int. J. Cancer 99 (4): 520–8.
(4) Hakuma, N. et al., 2007, Oncology. 72 : 197-204.
更多信息或购买 :
公司信息
ACROBiosystems
1 Innovation Way Newark, DE 19711, USA
order@acrobiosystems.com
http://www.acrobiosystems.com1-800-810-0816
ACROBiosystems is a leading manufacturer of recombinant proteins and other critical reagents to support the development of target therapeutics, vaccines and diagnostic kits.
Our team has worked tirelessly since the genomic sequence of SARS-CoV-2 was first published, developing a serial of critical reagents to fight COVID-19. Our team has successfully developed a new neutralizing antibody titer serologic assay kit for COVID-19 vaccine evaluation (Cat.No.TAS-K022) which really showed excellent performance.
As the emerging variants may have impacted on the development of the COVID-19 epidemic, our team is also going full steam ahead on developing a collection of spike mutants for the emerging variants of SARS-COV-2. The reagents can be used to evaluate the efficacy of the antibodies and vaccination.
We have also developed an extensive collection of recombinant proteins to support the development for bispecific antibodies, antibody drug conjugates and cell therapies.
Our team has worked tirelessly since the genomic sequence of SARS-CoV-2 was first published, developing a serial of critical reagents to fight COVID-19. Our team has successfully developed a new neutralizing antibody titer serologic assay kit for COVID-19 vaccine evaluation (Cat.No.TAS-K022) which really showed excellent performance.
As the emerging variants may have impacted on the development of the COVID-19 epidemic, our team is also going full steam ahead on developing a collection of spike mutants for the emerging variants of SARS-COV-2. The reagents can be used to evaluate the efficacy of the antibodies and vaccination.
We have also developed an extensive collection of recombinant proteins to support the development for bispecific antibodies, antibody drug conjugates and cell therapies.